B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP
- Madrigal Pharmaceuticals price target raised to $475 from $400 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi
- Madrigal price target raised to $405 from $400 at H.C. Wainwright
- Cautious Outlook on Madrigal Pharmaceuticals Amid Potential Overvaluation and Competitive Pressures